156P Safety/tolerability and Antitumor Activity of Sitravatinib Plus Tislelizumab in Patients with PD-(L)1-refractory/resistant Unresectable or Metastatic Melanoma from a Phase Ib Study
C. Cui,H. Pan,M. S. Carlino,J. Cui,X. Wang,X. Li,J. Sun,L. Yang,J. Guo
DOI: https://doi.org/10.1016/j.annonc.2021.10.175
IF: 51.769
2021-01-01
Annals of Oncology
Abstract:BackgroundSitravatinib, a selective multiple-target tyrosine kinase inhibitor, reduces the number of myeloid-derived suppressor and regulatory T cells and increases the ratio of M1/M2-polarized macrophages, which may augment antitumor responses. Tislelizumab, an anti-PD-1 antibody engineered to minimize binding to FcγR on macrophages, has shown clinical activity in patients with advanced solid tumors, including melanoma. This Phase 1b study assessed safety/tolerability and antitumor activity of sitravatinib + tislelizumab in advanced solid tumors (NCT03666143). We report results from the melanoma cohort.MethodsEligible patients (pts) had unresectable or metastatic melanoma that progressed on or after prior first-line anti-PD-1/PD-L1 monotherapy. Pts received oral sitravatinib 120 mg once daily and tislelizumab 200 mg IV Q3W until disease progression, unacceptable toxicity, death or withdrawal. The primary endpoint was safety/tolerability and key secondary endpoints were investigator-assessed objective response rate (ORR), disease control rate (DCR), and progression-free survival (PFS).ResultsAs of March 29, 2021, 25 pts were enrolled; 10 pts (40.0%) remained on treatment. Median study follow-up was 9.6 months (range: 5.6–18.8). Median age was 51 years (range: 23–79), 52.0% of pts were male and all pts received one prior line of PD-(L)1 treatment. Treatment-emergent adverse events (TEAEs) of any Grade/≥ Grade 3 were reported in 100.0%/52.0% of pts. Serious TEAEs were observed in 12.0% of pts (n=3) and no TEAE led to death. The most common ≥ Grade 3 TEAE was hypertension (n=4;16.0%). Confirmed ORR was 36.0% (95% CI 18.0–57.5) with one pt achieving a complete response and eight pts a partial response. DCR was 88.0% (95% CI 68.8–97.5) and median PFS was 6.7 months (95% CI 4.1– not evaluable).ConclusionsWith a longer follow-up period, the combination of sitravatinib + tislelizumab showed a manageable safety/tolerability profile and demonstrated antitumor activity in patients with R/R unresectable or metastatic melanoma previously treated with a PD-(L)1 inhibitor.Clinical trial identificationNCT03666143.Editorial acknowledgementThe authors would like to thank Xiao Xiang and Cheng Chen for their contributions to the study. Medical writing support for the development of this abstract, under direction of the authors, was provided by Louise Oakes, PhD, of Ashfield MedComms, an Ashfield Health company, and was funded by BeiGene Ltd.Legal entity responsible for the studyBeiGene Ltd.FundingBeiGene Ltd.DisclosureM.S. Carlino: Financial Interests, Personal, Advisory Board: Amgen, Bristol Myers Squibb, Eisai, Ideaya, MSD, Nektar, Novartis, Oncosec, Pierre-Fabre, Qbiotics, Regeneron, Roche, Merck and Sanofi. X. Wang: Other, Institutional, Funding: Oriengene; Financial Interests, Personal and Institutional, Advisory Board: Oriengene. X. Li: Financial Interests, Personal, Full or part-time Employment: BeiGene. L. Yang: Financial Interests, Personal, Full or part-time Employment: BeiGene; Financial Interests, Personal, Stocks/Shares: BeiGene. J. Guo: Financial Interests, Personal and Institutional, Advisory Board: MSD, Roche, Pfizer, Bayer, Novartis, Simcere, Shanghai Junshi Bioscience, Oriengene. All other authors have declared no conflicts of interest. BackgroundSitravatinib, a selective multiple-target tyrosine kinase inhibitor, reduces the number of myeloid-derived suppressor and regulatory T cells and increases the ratio of M1/M2-polarized macrophages, which may augment antitumor responses. Tislelizumab, an anti-PD-1 antibody engineered to minimize binding to FcγR on macrophages, has shown clinical activity in patients with advanced solid tumors, including melanoma. This Phase 1b study assessed safety/tolerability and antitumor activity of sitravatinib + tislelizumab in advanced solid tumors (NCT03666143). We report results from the melanoma cohort. Sitravatinib, a selective multiple-target tyrosine kinase inhibitor, reduces the number of myeloid-derived suppressor and regulatory T cells and increases the ratio of M1/M2-polarized macrophages, which may augment antitumor responses. Tislelizumab, an anti-PD-1 antibody engineered to minimize binding to FcγR on macrophages, has shown clinical activity in patients with advanced solid tumors, including melanoma. This Phase 1b study assessed safety/tolerability and antitumor activity of sitravatinib + tislelizumab in advanced solid tumors (NCT03666143). We report results from the melanoma cohort. MethodsEligible patients (pts) had unresectable or metastatic melanoma that progressed on or after prior first-line anti-PD-1/PD-L1 monotherapy. Pts received oral sitravatinib 120 mg once daily and tislelizumab 200 mg IV Q3W until disease progression, unacceptable toxicity, death or withdrawal. The primary endpoint was safety/tolerability and key secondary endpoints were investigator-assessed objective response rate (ORR), disease control rate (DCR), and progression-free survival (PFS). Eligible patients (pts) had unresectable or metastatic melanoma that progressed on or after prior first-line anti-PD-1/PD-L1 monotherapy. Pts received oral sitravatinib 120 mg once daily and tislelizumab 200 mg IV Q3W until disease progression, unacceptable toxicity, death or withdrawal. The primary endpoint was safety/tolerability and key secondary endpoints were investigator-assessed objective response rate (ORR), disease control rate (DCR), and progression-free survival (PFS). ResultsAs of March 29, 2021, 25 pts were enrolled; 10 pts (40.0%) remained on treatment. Median study follow-up was 9.6 months (range: 5.6–18.8). Median age was 51 years (range: 23–79), 52.0% of pts were male and all pts received one prior line of PD-(L)1 treatment. Treatment-emergent adverse events (TEAEs) of any Grade/≥ Grade 3 were reported in 100.0%/52.0% of pts. Serious TEAEs were observed in 12.0% of pts (n=3) and no TEAE led to death. The most common ≥ Grade 3 TEAE was hypertension (n=4;16.0%). Confirmed ORR was 36.0% (95% CI 18.0–57.5) with one pt achieving a complete response and eight pts a partial response. DCR was 88.0% (95% CI 68.8–97.5) and median PFS was 6.7 months (95% CI 4.1– not evaluable). As of March 29, 2021, 25 pts were enrolled; 10 pts (40.0%) remained on treatment. Median study follow-up was 9.6 months (range: 5.6–18.8). Median age was 51 years (range: 23–79), 52.0% of pts were male and all pts received one prior line of PD-(L)1 treatment. Treatment-emergent adverse events (TEAEs) of any Grade/≥ Grade 3 were reported in 100.0%/52.0% of pts. Serious TEAEs were observed in 12.0% of pts (n=3) and no TEAE led to death. The most common ≥ Grade 3 TEAE was hypertension (n=4;16.0%). Confirmed ORR was 36.0% (95% CI 18.0–57.5) with one pt achieving a complete response and eight pts a partial response. DCR was 88.0% (95% CI 68.8–97.5) and median PFS was 6.7 months (95% CI 4.1– not evaluable). ConclusionsWith a longer follow-up period, the combination of sitravatinib + tislelizumab showed a manageable safety/tolerability profile and demonstrated antitumor activity in patients with R/R unresectable or metastatic melanoma previously treated with a PD-(L)1 inhibitor. With a longer follow-up period, the combination of sitravatinib + tislelizumab showed a manageable safety/tolerability profile and demonstrated antitumor activity in patients with R/R unresectable or metastatic melanoma previously treated with a PD-(L)1 inhibitor.